GlassScriptPhysician profile
Arshia Sadreddin
NPI 1033308903
$95,389.34
in general payments reported to CMS, 2019-2025
27 companies · $448 in 2025
The $448 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $16K · 2021: $23K · 2022: $21K · 2023: $8,164 · 2024: $2,146 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,600 · Food and Beverage: $1,940 · Travel and Lodging: $1,820 · Education: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,600.00 |
| Food and Beverage | $1,939.59 |
| Travel and Lodging | $1,820.02 |
| Education | $1,398.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $52,666.66 | 2019-2024 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $27,925.89 | 2019-2024 | Inbrija |
| Boston Scientific Corporation | $10,547.00 | 2020-2025 | Vercise, General - Dbs, Suretek |
| Amneal Pharmaceuticals LLC | $1,441.98 | 2019-2024 | Ongentys 50mg Capsules 30, Ongentys, Crexont |
| Medtronic USA, INC. | $978.07 | 2019-2020 | |
| Medtronic, INC. | $459.21 | 2022-2024 | Percept PC Brainsense |
| Abbvie INC. | $331.64 | 2022-2025 | Botox |
| Sk Life Science, INC. | $92.91 | 2020-2021 | |
| Adamas Pharmaceuticals, INC. | $89.83 | 2019-2020 | |
| Allergan, INC. | $83.14 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $72.69 | 2019-2021 | |
| Eisai INC. | $68.71 | 2019 | |
| Amgen INC. | $67.26 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $61.97 | 2019 | |
| Livanova USA, INC. | $60.67 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $57.55 | 2019-2021 | |
| Abbott Laboratories | $57.43 | 2024 | Infinity |
| Bausch Health US, LLC | $45.65 | 2019 | |
| Sunovion Pharmaceuticals INC. | $43.47 | 2022 | |
| Lilly USA, LLC | $43.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.20 | 2019 | |
| Mdd US Operations, LLC | $42.80 | 2019 | |
| Kyowa Kirin, INC. | $37.50 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $23.51 | 2021 | |
| Aquestive Therapeutics, INC. | $19.88 | 2019 | |
| Greenwich Biosciences, INC. | $15.60 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshia Sadreddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.